4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid | 329746-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: 4-[7-(3,4-methylenedioxybenzylamino)-1-methyl-3-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid
• 英文别名: 4-[7-(1,3-Benzodioxol-5-ylmethylamino)-1,3-dimethylpyrazolo[4,3-d]pyrimidin-5-yl]butanoic acid
• CAS: 329746-32-9
• 化学式: C₁₉H₂₁N₅O₄
• 分子量: 383.407
• InChiKey: PXTUUTLPFWCRFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  111
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Pharmacuetical formulation comprising puyrazolo[4,-3-d]pyrimidines and antithrombotics, calcium antagonists, or prostaglandins or prostaglandin derivatives
  申请人：——

  公开号：US20040063730A1

  公开（公告）日：2004-04-01

  The invention relates to a pharmaceutical preparation containing at least one compound of formula (I), wherein R1, R2, R3, R4 and X have the meanings as cited in claim No. 1, and to their physiologically safe salts and/or solvates, and containing; a) at least one antithrombotic agent or; b) at least one calcium antagonist or; c) at least on prostaglandin or prostaglandin derivative for producing a medicament used for treating angina, hypertension, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, right ventricular failure, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, cerebrovascular accident, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumors, kidney failure, cirrhosis of the liver, and for treating female sexual dysfunctions. 1

  本发明涉及一种制药制剂，其中含有至少一种式（I）的化合物，其中R1、R2、R3、R4和X的含义如权利要求书第1号所述，并且含有生理安全的盐和/或溶剂，包括：a）至少一种抗血栓剂或；b）至少一种钙拮抗剂或；c）至少一种前列腺素或前列腺素衍生物，用于制备用于治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心室衰竭、动脉粥样硬化、心血管疾病血管通透性降低、外周血管疾病、脑血管意外、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能衰竭、肝硬化和治疗女性性功能障碍的药物。
• Use of pyrazolo[4,3-d]pyrimidines
  申请人：——

  公开号：US20040023991A1

  公开（公告）日：2004-02-05

  The invention relates to the use of pyrazolo[4,3-d]pyrimidines of formula (I), and the physiologically acceptable salts and/or solvates thereof, for producing a medicament for treating cancer.

  本发明涉及使用式（I）的吡唑并［4,3-d］嘧啶化合物及其生理上可接受的盐和/或溶剂化物，用于制备治疗癌症的药物。
• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
  申请人：——

  公开号：US20040077664A1

  公开（公告）日：2004-04-22

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor and at least one nitrate for the preparation of a medicament for the treatment of angina, high blood pressure, pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency and liver cirrhosis.

  含有至少一种磷酸二酯酶V抑制剂和至少一种硝酸盐的药物制剂，用于制备治疗心绞痛、高血压、肺动脉高压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管通路通畅度降低、外周血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全和肝硬化的药物。
• Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
  申请人：——

  公开号：US20040063731A1

  公开（公告）日：2004-04-01

  Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.

  含有至少一种磷酸二酯酶V抑制剂，和/或其生理上可接受的盐和/或溶剂，以及至少一种内皮素受体拮抗剂的制药制剂，用于制备治疗心绞痛、高血压、高肺动脉压、充血性心力衰竭（CHF）、慢性阻塞性肺疾病（COPD）、肺心病、右心衰竭、动脉粥样硬化、心血管疾病血管通透性降低、周围血管疾病、中风、支气管炎、过敏性哮喘、慢性哮喘、过敏性鼻炎、青光眼、肠易激综合征、肿瘤、肾功能不全、肝硬化、勃起功能障碍和治疗女性性功能障碍的药物。
• PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
  申请人：MERCK PATENT GmbH

  公开号：EP1357915A2

  公开（公告）日：2003-11-05